Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
Innovent Biologics (IVBIY) announced clinical updates for IBI324 (OLN324), their next-generation VEGF/Ang2 bispecific antibody being developed with partner Ollin. The JADE Phase 1b trial has completed enrollment of over 150 patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME).
The study aims to evaluate IBI324's potential advantages over faricimab, with topline results expected in Q1 2026. IBI324 features higher anti-Ang2 potency and higher molar doses than faricimab, potentially offering improved disease control and extended treatment durability. A previous Phase 1 study showed promising vision and anatomic improvements in DME patients with a favorable safety profile.
Innovent Biologics (IVBIY) ha comunicato aggiornamenti clinici su IBI324 (OLN324), la loro bispecifica di prossima generazione VEGF/Ang2 sviluppata in collaborazione con Ollin. Lo studio JADE Phase 1b ha completato l'arruolamento di oltre 150 pazienti con neovascolarizzazione coroideale wet (wAMD) o edema maculare diabetico (DME).
Lo studio mira a valutare i potenziali vantaggi di IBI324 rispetto a faricimab, con risultati preliminari attesi nel primo trimestre del 2026. IBI324 presenta una maggiore potenza anti-Ang2 e dosi molari superiori rispetto a faricimab, con potenziale miglior controllo della malattia e maggiore durabilità del trattamento. Uno studio di fase 1 precedente ha mostrato miglioramenti visivi e anatomici incoraggianti nei pazienti con DME, con profilo di sicurezza favorevole.
Innovent Biologics (IVBIY) anunció actualizaciones clínicas para IBI324 (OLN324), su anticuerpo bispecífico VEGF/Ang2 de próxima generación desarrollado con el socio Ollin. El ensayo JADE Phase 1b ha completado la inscripción de más de 150 pacientes con degeneración macular húmeda (wAMD) o edema macular diabético (DME).
El estudio tiene como objetivo evaluar las posibles ventajas de IBI324 frente a faricimab, con resultados de inicio esperados en el primer trimestre de 2026. IBI324 presenta una mayor potencia anti-Ang2 y dosis molares más altas que faricimab, lo que podría ofrecer un mejor control de la enfermedad y una mayor durabilidad del tratamiento. Un estudio de fase 1 anterior mostró mejoras visuales y anatómicas prometedoras en pacientes con DME y un perfil de seguridad favorable.
Innovent Biologics (IVBIY)가 Ollin과 함께 개발 중인 차세대 VEGF/Ang2 이중 특이 항체 IBI324(OLN324)에 대한 임상 업데이트를 발표했습니다. JADE Phase 1b 임상은 황반변성(wAMD) 또는 당뇨병성 황반부종(DME)을 가진 150명 이상을 모집 완료했습니다.
이 연구의 목표는 faricimab에 대한 IBI324의 잠재적 이점을 평가하는 것이며 주요 결과는 2026년 1분기 예정입니다. IBI324는 anti-Ang2 활성이 더 높고 faricimab보다 몰 등가 용량이 더 많아 질병 조절 및 치료 지속성을 개선할 수 있습니다. 이전의 1상 연구에서는 DME 환자에서 시력 및 해부학적 개선이 유망하게 나타났고 안전성 프로필도 양호했습니다.
Innovent Biologics (IVBIY) a annoncé des mises à jour cliniques pour l'IBI324 (OLN324), leur anticorps bispécifique VEGF/Ang2 de nouvelle génération développé avec leur partenaire Ollin. L'essai JADE Phase 1b a terminé l'inclusion de plus de 150 patients atteints de dégénérescence maculaire humide (wAMD) ou d'œdème maculaire diabétique (DME).
L'étude vise à évaluer les avantages potentiels d'IBI324 par rapport au faricimab, avec des résultats pragmatiques attendus au premier trimestre 2026. IBI324 présente une puissance anti-Ang2 plus élevée et des dosages molaires supérieurs à ceux du faricimab, ce qui pourrait offrir un meilleur contrôle de la maladie et une durabilité du traitement accrue. Une étude de phase 1 précédente a montré des améliorations visuelles et anatomiques prometteuses chez les patients atteints de DME, avec un profil de sécurité favorable.
Innovent Biologics (IVBIY) hat klinische Updates zu IBI324 (OLN324) bekannt gegeben, ihrem Next-Generation-VEGF/Ang2-Bispektrum-Antikörper, der gemeinsam mit Partner Ollin entwickelt wird. Die JADE Phase 1b-Studie hat die Einschreibung von über 150 Patienten mit feuchter AMD (wAMD) oder diabetischem Makulaödem (DME) abgeschlossen.
Die Studie zielt darauf ab, die potenziellen Vorteile von IBI324 gegenüber Faricimab zu bewerten, mit erstem Topline-Ergebnis im Q1 2026. IBI324 verfügt über eine höhere Anti-Ang2-Potenz und höhere molare Dosen als Faricimab, was potenziell eine verbesserte Krankheitskontrolle und eine längere Behandlungsdauer ermöglicht. Eine frühere Phase-1-Studie zeigte vielversprechende Seh- und anatomische Verbesserungen bei DME-Patienten mit sicherem Sicherheitsprofil.
Innovent Biologics (IVBIY) أعلنت عن تحديثات سريرية لـ IBI324 (OLN324)، جسم مضاد ثنائي التخصص من الجيل التالي VEGF/Ang2 الذي يتم تطويره مع شريكته Ollin. تجربة JADE Phase 1b أكملت تسجيل أكثر من 150 مريضًا يعانون من التنكس البقعي الرطب (wAMD) أو وذمة البقعة الصفراء السكرية (DME).
تهدف الدراسة إلى تقييم المزايا المحتملة لـ IBI324 مقارنةً بفاريسيماب، مع نتائج أولية متوقعة في الربع الأول من 2026. يتميز IBI324 بفعالية مضاد Ang2 أعلى وتدرجات مولارية أعلى من فاريسيماب، ما قد يقدم سيطرة أفضل على المرض وديمومة علاج أطول. أظهرت دراسة مرحلية سابقة تحسنات في الرؤية والتشريح لدى مرضى DME مع ملف أمان مفضل.
Innovent Biologics (IVBIY) 宣布了关于 IBI324 (OLN324) 的临床更新，这是他们与 Ollin 合作开发的下一代 VEGF/Ang2 双特异性抗体。JADE Phase 1b 试验已完成超过 150 例湿性年龄相关性黄斑变性(wAMD)或糖尿病性黄斑水肿(DME)患者的入组。
该研究旨在评估 IBI324 相对于 faricimab 的潜在优势，预计 2026 年第1季度公布初步结果。IBI324 具有更高的 Anti-Ang2效力以及比 faricimab 更高的摩尔剂量，可能提供更好的疾病控制和更长的治疗持续性。先前的 Phase 1 研究在 DME 患者中显示出有希望的视觉与解剖学改善，安全性特征良好。
- None.
- Topline results not available until Q1 2026
- Still in early clinical development (Phase 1b)
Building on the proven backbone efficacy of anti-VEGF, OLN324's substantially higher anti-Ang2 potency over the current market leader faricimab, coupled with a smaller protein format, gives OLN324 the potential for best-in-class disease control. OLN324 is being tested at higher molar doses than faricimab for greater target coverage and the potential for extended treatment durability. These features give OLN324 the potential for a differentiated, first-line standard of care profile.
"Both VEGF and Ang2 play important roles in the vascular pathologies that drive wAMD and DME. Dual targeting has the potential to improve anatomic outcomes and achieve more durable disease control compared to VEGF inhibition alone. Uptake of the first
Dr. Lei Qian, Chief R&D Officer of General Biomedicine from Innovent Biologics, stated: "We are excited about by the progress of OLN324 (IBI324), driven forward by our partner Ollin—especially the successful enrollment completion of the JADE Phase 1b trial, which represents a key milestone that validates both parties' strong collaboration. As a next-generation VEGF/Ang-2 bispecific antibody, OLN324 (IBI324) holds promise for better anatomic outcomes and longer durability than current standards like faricimab. We remain aligned with Ollin to speed OLN324's development and bring this much needed therapy to market globally."
In a completed Phase 1 single and multiple dose escalation study, IBI324 (OLN324) demonstrated promising vision and anatomic improvements in DME patients along with a favorable safety profile. IBI324 (OLN324) was discovered by Innovent and is being developed in collaboration with Ollin.
About Ollin
Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what's possible in ophthalmology. For more information, please visit www.ollin.bio.
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content:https://www.prnewswire.com/news-releases/innovents-partner-ollin-announces-clinical-updates-on-ibi324-oln324-vegfang-2-302559062.html
SOURCE Innovent Biologics
FAQ
What is the current status of Innovent's IBI324 (OLN324) clinical trial?
How does IBI324 (OLN324) differ from faricimab?
What conditions does Innovent's IBI324 (OLN324) target?
What were the results of IBI324's Phase 1 study?
When will Innovent's IBI324 clinical trial results be available?
